

April 18, 2017.

To,
Asst. General Manager- Dept of Corp. Services,
Bombay Stock Exchange Ltd.
14th Floor, P.J. Towers,
Dalal Street, Fort,
Mumbai: 400001.

Respected Sir,

Scrip Code: 524500

Sub: Filing of Statement of Investor Complaints under Regulation 13(3) of SEBI (LODR) Regulations 2015 for the Quarter ended March 2017.

With reference to the captioned subject, we are filing herewith Statement of Investor Complaints under Regulation 13(3) of SEBI (LODR) Regulations 2015 for the Quarter ended March 2017.

We hope that the above meets with your requirements.

Thanking you,

Yours Faithfully,

For: KILITCH DRUGS (INDIA) LIMITED



**MUKUND MEHTA
MANAGING DIRECTOR.
DIN: 00147876**



Encl.a/a.



14th April 2017

To
Kilitch Drugs (India) Ltd.
37, Ujagar Industrial Estate,
W.T Patil Marg, Deonar,
Mumbai- 400 088

Dear Sir,

Sub : Investor Grievance report for the period 01.01.2017 to 31.03.2017.

Please refer the below Investor Grievance report for the period 01.01.2017 to 31.03.2017

Description of Investor Grievances for the quarter	No of Grievances
Total Grievances pending at the beginning of the quarter	NIL
Letters N/R/ of D/w, Interest / Redemption warrant	NIL
Correction in Refund Instrument	NIL
N.S.E	NIL
B.S.E	NIL
SEBI	NIL
Total Grievances attended	NIL
Total Grievances pending at the end of the quarter	NIL

Thanking You.

Yours faithfully
For Link Intime India Private Limited



Authorised Signatory